

Dear Friends and Collaborators of Protagen,

following on from a successful 2014, we are looking ahead to what promises to be an even better 2015. In December we informed you about the 1st Closing over our Financing Round, on this tailwind we will advance the development of further Multilisa[®] products. We are also aiming towards our ISO13485 certification and will tackle the pharma/biotech market together with Qiagen. As always we will inform you on our progress during these busy, interesting but also very promising times and look forward to staying in close contact with you throughout the year.

WE WISH YOU A HAPPY NEW YEAR 2015

New IVD Group



Johannes Schulte-Pelkum and Daniel Wirtz joined us from INOVA Diagnostics and Virion/Serion, respectively, and will build our new IVD team. Both have a lot of experience and expertise in developing CE marked and FDA approved IVD tests, especially for autoimmune indications and autoantibody detection. Protagen is now in a pole position to become a leading autoimmune Dx company, based on novel autoimmune markers with a strong IP base.

Conferences & Meet us @



We attended BioEurope in Frankfurt and the ACR meeting in Boston where we had the chance to present our latest results in RA and SSC. At the same time we engaged with numerous investors, collaborators, as well as Dx, Pharma and Biotech representatives. The New Year will start in similar fashion with our attendance at the JP Morgan and Biotech Showcase conferences in San Francisco, where we will have a presentation slot, and look forward to meeting you.

Corporate News & PR



Our PR and marketing campaign is gaining momentum and we will build on this in 2015. In December we participated in a publication on rare/orphan diseases which was released on December 11 as supplement to the Handelsblatt. As a result of our press release on the strategic partnership with Qiagen, we got recognition throughout the industry and industry news, e.g. Fierce, Bio Smart Brief, others, and an interview with Stefan was published in GenomeWeb on November 21, 2014.

Quarterly Update

The last quarter of 2014 was very busy and very successful for us: Significant milestones were reached and our recognition and reputation is growing on an ongoing basis which provides the basis to build on in 2015.

The Pfizer project is close to finalization and our ongoing development programs in RA, SLE, and SSC have progressed. For our SSC program the clinical development program with KOLs in the field from Zurich,

Cologne and Dresden is underway. In RA we reached an agreement with 3 cohort studies to advance our developments for our early diagnosis and response prediction programs.

News

Protagen Successfully Closes New Financing Round

PROTAGEN AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics in the autoimmune field, today announced the closing of a new financing round. In this round, QIAGEN N.V., joins existing investors ...

[READ MORE](#)

Protagen AG signs collaboration with QIAGEN to develop novel protein based CDx

Protagen AG today announced that it has entered into a long-term collaboration agreement with QIAGEN targeting the development of novel protein-based companion diagnostics for autoimmune disorders.

[READ MORE](#)

Finally – New Year Resolutions

A 2007 study by Richard Wiseman from the University of Bristol involving 3,000 people showed that 88% of those who set New Year resolutions fail, despite the fact that 52% of the study's participants were confident of success at the beginning.

